JAK inhibitors are anticipated to have therapeutic prospects in BP as pruritus and inflammatory skin lesions are both important features of BP, and there is increased expression of Th2 cytokines, such as IL-4, IL-5, IL-13, and IL-31, in BP patients. This evidence concerns the gene IL31 and Pruritus.